Cargando…

Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Michailidis, Theodoros, Dimosiari, Athina, Kassimis, George, Fragakis, Nikolaos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713326/ https://www.ncbi.nlm.nih.gov/pubmed/36465144 http://dx.doi.org/10.1016/j.ijcrp.2022.200161

Ejemplares similares

Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Patoulias, Dimitrios, et al.
Publicado: (2023)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Takayasu Arteritis is Associated with Impaired Arterial Stiffness: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed?
por: Dimosiari, Athina, et al.
Publicado: (2022)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

Effect of COVID-19 on endothelial function evaluated with flow-mediated dilation: another prognostic marker? A meta-analysis of observational studies
por: Dimosiari, Athina, et al.
Publicado: (2022)

Intravenous pulse methylprednisolone for the treatment of severe COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2023)

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
por: Dimosiari, Athina, et al.
Publicado: (2023)

Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation
por: Ţica, Otilia, et al.
Publicado: (2022)

Anti-Interleukins for Severe Coronavirus Disease-2019: Hype or Hope?
por: Dimosiari, Athina, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis
por: van den Berg, Maarten P, et al.
Publicado: (2019)

The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction
por: Weerts, Jerremy, et al.
Publicado: (2021)

Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction
por: Liu, Xiao, et al.
Publicado: (2022)

Rhythm versus rate control for atrial fibrillation in heart failure with preserved ejection fraction
por: Al-Sadawi, Mohammed, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions
por: Fauchier, Laurent, et al.
Publicado: (2023)

Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction
por: Kuo, Jen-Yuan, et al.
Publicado: (2022)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
por: Brust-Sisti, Lindsay, et al.
Publicado: (2022)

Effects of rhythm control on left atrial structure remodeling in atrial fibrillation and heart failure with preserved ejection fraction
por: Bai, Lin, et al.
Publicado: (2023)

Atrial Fibrillation and Outcomes in Heart Failure With Preserved Versus Reduced Left Ventricular Ejection Fraction
por: McManus, David D., et al.
Publicado: (2013)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Heart failure with preserved ejection fraction: An alternative paradigm to explain the clinical implications of atrial fibrillation
por: Ariyaratnam, Jonathan P., et al.
Publicado: (2021)

Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
por: Gierula, John, et al.
Publicado: (2022)

Atrial fibrillation ablation in patients with heart failure with preserved ejection fraction: Complexities in diagnosis and treatment
por: Ariyaratnam, Jonathan P., et al.
Publicado: (2022)

Outcomes of patients with heart failure with preserved ejection fraction undergoing catheter ablation of atrial fibrillation
por: Krishnamurthy, Amrita, et al.
Publicado: (2022)

Safety, Efficacy and Prognostic Benefit of Atrial Fibrillation Ablation in Heart Failure with Preserved Ejection Fraction
por: Johner, Nicolas, et al.
Publicado: (2022)

Cryoballoon ablation for atrial fibrillation in patients with heart failure with mildly reduced and preserved ejection fraction
por: Chen, Chaofeng, et al.
Publicado: (2022)

The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
por: Androulakis, Emmanuel, et al.
Publicado: (2022)

Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study
por: Gatzoulis, Konstantinos A, et al.
Publicado: (2019)

Addressing the Challenge of Atrial Fibrillation Management: How to Differentiate the Approach Depending on Left Ventricular Ejection Fraction
por: De Vecchis, Renato, et al.
Publicado: (2019)

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

Loss of myeloid differentiation protein 1 promotes atrial fibrillation in heart failure with preserved ejection fraction
por: Shuai, Wei, et al.
Publicado: (2020)

Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction: A meta‐analysis
por: Gu, Gaoyang, et al.
Publicado: (2022)

Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction
por: Yang, Eunice, et al.
Publicado: (2022)

Long‐term events following catheter‐ablation for atrial fibrillation in heart failure with preserved ejection fraction
por: Ishiguchi, Hironori, et al.
Publicado: (2022)

Impact of catheter ablation for persistent atrial fibrillation with heart failure, compared to preserved and reduced ejection fraction
por: Inamura, Y, et al.
Publicado: (2023)

Relationships of Atrial Fibrillation at Diagnosis and Type of Atrial Fibrillation During Follow-up With Long-Term Outcomes for Heart Failure With Preserved Ejection Fraction
por: Nakatani, Daisaku, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6h4265r0boai20ihrmpq3m3ce8